Cardiff Oncology shares plunge after Q2 earnings miss
Charles E. McLaughlin, the Senior Vice President and Chief Financial Officer of Fortive Corp (NYSE:FTV), recently executed a significant stock transaction. According to a recent SEC filing, McLaughlin sold 32,085 shares of Fortive common stock on February 28, 2025, at a weighted average price of $78.86 per share, generating approximately $2.53 million. The transaction comes as Fortive, currently valued at $26.29 billion, maintains strong gross profit margins of nearly 60% and a solid financial health rating according to InvestingPro analysis.
Additionally, McLaughlin exercised options to acquire 16,467 shares of common stock at $35.84 per share, totaling around $590,177. Following these transactions, McLaughlin’s direct ownership of Fortive stock now stands at 73,486 shares.
The transactions also included the withholding of 2,640 shares for tax purposes related to the vesting of restricted stock units, valued at $209,985 based on a price of $79.54 per share.
These moves come as part of McLaughlin’s ongoing management of his holdings in the company. Fortive Corp, based in Everett, Washington, specializes in industrial instruments for measurement, display, and control. For deeper insights into Fortive’s valuation and performance metrics, investors can access the comprehensive Pro Research Report, available exclusively on InvestingPro, which covers over 1,400 US stocks with detailed analysis and actionable intelligence.
In other recent news, Fortive Corporation reported its fourth-quarter earnings, revealing a revenue of $1.62 billion, which slightly missed the consensus estimate of $1.63 billion. Despite this, the company exceeded expectations with an adjusted earnings per share of $1.17, compared to the anticipated $1.12. Fortive’s guidance for 2025 projects revenue between $6.23 billion and $6.35 billion, falling short of Wall Street’s forecast of $6.47 billion. Additionally, the company expects adjusted EPS for 2025 to be in the range of $4.00 to $4.12, slightly below the consensus of $4.12. RBC Capital Markets raised Fortive’s stock price target from $77.00 to $85.00, maintaining a Sector Perform rating, while Raymond (NSE:RYMD) James increased its target from $85.00 to $90.00, sustaining an Outperform rating. Fortive also announced the appointment of Gregory J. Moore, M.D., Ph.D., to its Board of Directors, expanding the board from nine to ten members. Dr. Moore’s expertise in AI and healthcare is anticipated to support Fortive’s strategic growth initiatives. The company plans to complete the spin-off of its Precision Technologies segment into a new entity, Ralliant, earlier than expected, now set for the third quarter of 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.